Ekso Bionics Holdings, Inc. — Q3 2019 Form 10-Q
Reporting period: Three and nine months ended September 30, 2019. Unless noted otherwise, amounts are in U.S. dollars; financial statement figures are in thousands. Ekso designs and sells exoskeletons for medical rehabilitation and industrial use. The filing is by Ekso Bionics Holdings, Inc.; the request metadata names a different company.
Financial performance and liquidity
| Metric | Q3 2019 | Q3 2018 | Nine months 2019 | Nine months 2018 |
|---|---|---|---|---|
| Revenue | $3.319m | $2.550m | $10.197m | $8.036m |
| Gross profit | $1.750m | $1.083m | $4.909m | $2.819m |
| Gross margin | 52.7% | 42.5% | 48.1% | 35.1% |
| Operating loss | $(3.790)m | $(6.094)m | $(13.800)m | $(21.891)m |
| Net income (loss) | $0.206m | $(6.983)m | $(9.411)m | $(22.860)m |
| Cash used in operations | Not presented for the quarter | Not presented for the quarter | $(14.277)m | $(17.011)m |
- Q3 revenue rose 30%, chiefly from EksoHealth medical device sales and rental-to-sale conversions; EksoWorks revenue fell amid delayed customer purchasing decisions. Nine-month revenue increased 27%. Medical segment revenue was $8.635m for the nine months, while industrial segment revenue was $1.536m.
- Gross profit and margins improved as Ekso reported higher average selling prices and lower production costs for EksoGT and EksoNR. Operating expenses declined 23% in Q3 and 24% year to date, reflecting lower headcount and other cost reductions.
- Q3 net income included a $4.430m gain from revaluing warrant liabilities; the nine-month gain was $6.045m. These fair-value gains were driven primarily by the decline in the share price and are not an indication of operating profitability. Ekso remained loss-making from operations and reported a nine-month net loss.
- Cash was $8.058m at September 30, versus $7.655m at year-end 2018. Debt was $3.305m net, including $2.333m current; warrant liabilities were $2.131m. Operating lease liabilities totaled $1.223m.
- Cash provided by financing was $14.770m for the nine months, mainly from equity issuance, including the May public offering, ATM sales and the China-related share purchase, partly offset by $1.783m of debt principal payments. The company issued shares and warrants; common shares outstanding increased to 74.953m from 62.963m at December 31, 2018.
Management commentary, outlook and material risks
- Management stated that forecast cash would not fund operations for the next 12 months from issuance of the statements, creating substantial doubt about the company’s ability to continue as a going concern. After the debt covenant cash restriction of $4.372m, estimated unrestricted cash was $3.686m. Management expected resources to support operations while complying with debt covenants into Q1 2020, assuming modest revenue increases, but said significant additional financing was required.
- Ekso was pursuing equity, debt and collaboration financing. Financing may not be available on acceptable terms or at all; additional equity could dilute shareholders. Without financing, the company may need substantial expense cuts or to curtail operations. No specific revenue or earnings guidance was provided.
- Nasdaq notified Ekso that its share price did not meet the $1.00 minimum bid requirement. The initial compliance period ran through March 16, 2020; failure to regain compliance could lead to delisting and impair liquidity and access to financing.
- The China joint venture and related investment were subject to potential U.S. government review. Ekso planned to submit a joint voluntary notice to CFIUS; review, mitigation, export-control licensing or a requirement to unwind the arrangement could delay or restrict the venture and technology transfers. An October 22, 2019 technology license agreement provided for royalties after a specified royalty-free period.
- Product and commercial developments included the August introduction of EksoNR, the next-generation lower-extremity rehabilitation device, and the July announcement of EksoUE for upper-extremity rehabilitation. Ekso booked 23 EksoNR and EksoGT units in Q3, including rental units and units converted from rentals to sales.
- Other notable items: adoption of lease accounting added right-of-use assets and lease liabilities without material effect on earnings or cash flows; a conditional Singapore government grant of approximately $1.5m had not been received or recognized as revenue; and the filing reported no material adverse effect expected from disclosed legal matters. Management said disclosure controls were effective and reported no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Updated cash runway, unrestricted cash and compliance with the debt liquidity covenant, alongside progress and terms of any new financing.
- Whether Ekso regained Nasdaq’s minimum bid-price compliance by the deadline and whether any further listing actions were required.
- Status and outcome of CFIUS and export-control review, China JV registration, IP transfer, partner funding and the contingent additional $5m share investment.
- Whether medical device sales growth and improved margins can continue, and whether delayed EksoWorks customer decisions convert into orders.
- Effect of warrant remeasurement, warrant terms and potential future share issuance on reported results and shareholder dilution.